Further research published in 2005 suggested that those that underwent surgery for the disease before the menopause were much more likely to relapse. This could explain the disparity in mortality. He also observed that African patients presented with the disease within their early 40s, although no-one has yet identified why black women get the disease earlier. Now we need further research to verify these observations before we explore any required changes in practice.S.A, Romano Demicheli, of the Istituto Nazionale Tumori, Milan, and William Hrushesky of the University of South Carolina, U.S.A..This may fulfill important medical needs in type 2 diabetes and be extremely complementary to existing therapeutic classes, gLP-1 agonists especially. They support the advancement of AZP-531 as a new therapeutic approach in metabolic indications. She added: Our next thing is to deliver preliminary basic safety and efficacy data in type 2 diabetes individuals and in patients with Prader-Willi syndrome. The trials in healthy volunteers, in overweight/obese topics and in type 2 diabetes individuals are parts of a mixed protocol authorized by the Medicine and Healthcare Regulatory Authority in the united kingdom..